Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

Abstract Background Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the response to anti-PD-1 immunotherapy in HCC are still unclear. Herein, we r...

Full description

Bibliographic Details
Main Authors: Yi Zheng, Tingting Wang, Xiaoxuan Tu, Yun Huang, Hangyu Zhang, Di Tan, Weiqin Jiang, Shunfeng Cai, Peng Zhao, Ruixue Song, Peilu Li, Nan Qin, Weijia Fang
Format: Article
Language:English
Published: BMJ Publishing Group 2019-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Gut microbiome
Hepatocellular carcinoma
Anti-PD-1 immunotherapy
Online Access:http://link.springer.com/article/10.1186/s40425-019-0650-9

Internet

http://link.springer.com/article/10.1186/s40425-019-0650-9

Similar Items